Interim data published in Haemophilia show improvements in long-term joint health for haemophilia A patients after prophylactic treatment with Elocta®
Positive results seen in study participants regardless of prior treatment regimen, severity of joint damage or target joints First study to demonstrate continuous improvement in joint health with an extended half-life factor therapySwedish Orphan Biovitrum AB (publ) (Sobi™)(STO:SOBI) and Bioverativ Inc. (NASDAQ: BIVVV) today announces the publication of interim results from a longitudinal study of joint health in patients treated prophylactically with Elocta® (efmoroctocog alfa)/ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion